Observational Study in HCV Chronic Infection
Prospective Multicentric Observational Study in HCV Chronic Infected Patients.
HCV infection is the most frequent cause of liver chronic disease, cirrhosis and hepatocellular carcinoma in western countries.
To date, the standard antiviral treatment, including pegylated interferon (PEG-IFN) plus ribavirin (RBV), has relatively low effectiveness in patients infected with genotype 1 and 4, and is associated with important adverse side effects, that lead to treatment interruption in approximately 30% of cases.
The recent association of first generation HCV- specific direct-acting antiviral agents (DAAs) (telaprevir and boceprevir) to standard treatment has resulted in higher SVR rates, also in patients infected with genotype-1 HCV and in non responders to PEG-IFN plus RBV. While several new DAAs are in development, the ultimate goal is represented by IFN-free regimens, that will provide a great advantage in terms of patients adherence to therapy and quality of life.
In this context, prospective observational studies are needed to evaluate the real and long-term impact of the new DAAs in the clinical practice, in terms of efficacy, safety, costs and impact on patients quality of life.
Italy is the European country with the greatest number of HCV infected people (average, 3% of population), with higher prevalence in the center and in the south of the country, especially in older individuals, and the highest mortality caused by hepatocellular carcinoma. Genotype 1 is the most frequent one (in more than 50% of infected people). DAAs were approved at the end of 2012. For these reasons, Italy represents an interesting context for collecting data on long-term efficacy, safety and tolerability of new anti-HCV treatments.
The PITER cohort study, developed in the frame of Italian Platform for the study of the therapy of viral hepatitis a prospective observational study, is based on a large cohort of HCV infected patients from more than 100 clinical centers distributed on the whole national area.
The main aims of the PITER longitudinal cohort study are: 1) to produce of an ongoing and continuously updated picture of the changing epidemiology of HCV infection in the country; 2) to evaluate in a real-life setting the expected impact of DAAs on the natural course of infection and on long-term morbidity and mortality.
Přehled studie
Postavení
Podmínky
Detailní popis
Collected data will include clinical, laboratory and anatomopathological information and will be recorded in electronic CRF, at the enrollment and follow-up visits.
Special attention will be devoted to specific patient categories (with HIV, HBV, HDV and HEV coinfections, comorbidities, disease patients who presents signs of liver disease progression). Subjects starting an antiviral regimen will be followed according to specific guidelines.
A sub-study on quality of life/adherence to treatment/treatment satisfaction will be also conducted on all treated patients of the cohort.
Typ studie
Zápis (Aktuální)
Kontakty a umístění
Studijní místa
-
-
-
Rome, Itálie, 00161
- Istituto Superiore di Sanità
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Metoda odběru vzorků
Studijní populace
Patient characteristics: :
- any clinical and histopathologic stage of HCV infection
- infected by any HCV genotypes
- Untreated at the time of the enrolment (previously treated subjects are eligible)
- With/without HBV co-infection
- With/without HIV co-infection (in any clinical stage of HIV infection, with or without antiretroviral treatment)
Popis
Inclusion Criteria:
- All HCV infected patients who will consecutively come to the participating clinical centers in a given time span (enrollment periods)
Exclusion Criteria:
- Younger than 18 years
- Patients treated at the moment of the enrollment
Studijní plán
Jak je studie koncipována?
Detaily designu
- Observační modely: Kohorta
- Časové perspektivy: Budoucí
Kohorty a intervence
Skupina / kohorta |
|---|
|
Hepatitis-C infected patients
Patients with Hepatitis-C infection untreated at the enrolment
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Age distribution at recruitment
Časové okno: ten years
|
Age distribution will be expressed in years and reported as median
|
ten years
|
|
Sex distribution at recruitment
Časové okno: ten years
|
The sex distribution (males and females) will be reported as frequencies (percent)
|
ten years
|
|
BMI distribution at recruitment
Časové okno: ten years
|
The BMI (kg/m^2) will be expressed in the following cathegories: Underweight, Normal, Overweight, Obese and will be reported as frequencies (percent)
|
ten years
|
|
Genotype distribution at recruitment
Časové okno: ten years
|
Genotype distribution will be expressed in the following categories: 1 non subtyped, 1a, 1b, 2, 3, 4-5, and will be reported as frequencies (percent)
|
ten years
|
|
Liver disease stage at recruitment
Časové okno: ten years
|
The liver disease stage distribution will be expressed in the following chategories: F0-F3, F4-cirrhosis, decompensated cirrhosis, HCC, liver transplant, and will be reported as frequencies (percent)
|
ten years
|
|
Sustained virological response (SVR) in treated patients
Časové okno: ten years
|
Rates of SVR for each expected combination of DAAs used; identification of factors influencing HCV treatment response in the real life.
|
ten years
|
|
Changes in the severity of liver disease
Časové okno: ten years
|
Changes in liver function will be evaluated in terms of Child Pugh (C-P) score increase or decrease by 1 or more points, whatever occurred first after the end of treatment. This outcome will be expressed as proportions (percent) |
ten years
|
|
Incidence of Hepatocellular carcinoma (HCC)
Časové okno: ten years
|
Incidence of HCC will be evaluated on the basis of the first diagnosis reported after the end of treatment, excluding prevalent HCC cases occurred before treatment. Cumulative incidence will be expressed as proportions (percent) |
ten years
|
|
Incidence and recurrence of decompensated cirrhosis
Časové okno: ten years
|
Liver decompensating event is defined as the presence or appearance of ascites and/or portal hypertensive gastrointestinal bleeding and/or hepatic encephalopathy. Incidence of a decompensating event will be evaluated on the basis of the first occurrence after the end of treatment, excluding cases occurred before treatment. Recurrence of decompensation will be evaluated on the basis of the first events in patients with previous history of decompensated cirrhosis. Cumulative incidence or recurrence will be expressed as proportions (percent) |
ten years
|
Spolupracovníci a vyšetřovatelé
Sponzor
Vyšetřovatelé
- Vrchní vyšetřovatel: Loreta Kondili, MD, Istituto Superiore di Sanità
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia
Primární dokončení (Aktuální)
Dokončení studie (Aktuální)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Odhad)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
- PITER 01
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na Hepatitida C, chronická
-
National Taiwan University Hospital Hsin-Chu BranchNeznámýSelhání přístupu k hemodialýze | Krevní tlak | Porucha přístupu k dialýzeTchaj-wan
-
National Research Centre, EgyptFaculty of Medicine, Minia UniversityDokončeno
-
University of OttawaZatím nenabírámeAbsorpce pneumokokové vakcíny | Ochota k očkování | Znalost pneumokokové vakcíny | Postoj k vakcíně proti pneumokokůmKanada
-
University of LouisvilleKentucky Cabinet for Health & Family ServicesDokončenoOvládání seznamu čekatelů | Učební plán výchovy k rodičovství | Kurikulum výchovy k rodičovství + Case ManagementSpojené státy
-
National Cancer Institute (NCI)Aktivní, ne náborRakovina | Dědičné novotvary | Genetická predispozice k rakovině | Životní prostředíSpojené státy
-
Maastricht University Medical CenterDokončeno
-
InQpharm GroupDokončenoRegulace chuti k jídlu | Příjem energie | Potlačení chuti k jídluNěmecko
-
Hospital for Special Surgery, New YorkDokončenoPřipravenost k vybitíSpojené státy
-
Izmir University of EconomicsThe Scientific and Technological Research Council of TurkeyNáborNesnášenlivost k nejistotěKrocan
-
Assistance Publique - Hôpitaux de ParisMinistry of Health, FranceDokončeno